Pharmaceuticals | Total revenues by division – Q2
The Merck Group has two business sectors – Pharmaceuticals and Chemicals – each of which consists of two divisions.
The Pharmaceuticals business sector’s divisions are Merck Serono for innovative prescription medicines and Consumer Health Care for over-the-counter pharmaceutical products. The Pharmaceuticals business sector generated 71% of the company’s total revenues and 49% of the Group operating result during the second quarter. Total revenues for the Pharmaceuticals sector increased by 9.9% to EUR 1,564 million during the second quarter and by 8.2% to EUR 3,079 million during the first half of the year.
Again in the second quarter, the higher revenues recorded by Merck’s Pharmaceuticals business sector were due to increased sales of the top products in the Merck Serono division, especially the biotech medicines Rebif® and Erbitux®. Despite higher costs for marketing and selling and commissions and royalties, the business sector’s second-quarter operating result increased 17% to EUR 158 million compared to the year-ago quarter. The first-half operating result improved 6.0% to EUR 338 million.
IMS Health, the world’s leading provider of market intelligence for the pharmaceutical and healthcare industries, reported in its most recent forecast on April 20 that it expects the global pharmaceutical market to grow by 4% to 6% in 2010. IMS said the global market grew by 7.0% in 2009.